Search results for "RADIOTHERAPY"

showing 10 items of 473 documents

AGuIX modifications for active tumor targeting and radiolabelling

2014

International audience

Radiotherapy[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingActive targeting[SDV]Life Sciences [q-bio][SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesFunctionalisationImaging[SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences[SDV] Life Sciences [q-bio]Nanoparticle[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/ImagingTheranostic[SDV.CAN] Life Sciences [q-bio]/Cancer[CHIM] Chemical Sciences[CHIM]Chemical SciencesComputingMilieux_MISCELLANEOUSMRICancer
researchProduct

Functionalization of ultrasmall nanoparticles for theranosctic applications

2015

International audience

Radiotherapy[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging[SDV]Life Sciences [q-bio][SDV.CAN]Life Sciences [q-bio]/CancerGadolinium[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesFunctionalisationImaging[SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences[SDV] Life Sciences [q-bio]Nanoparticle[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/ImagingTheranostic[SDV.CAN] Life Sciences [q-bio]/Cancer[CHIM] Chemical Sciences[CHIM]Chemical SciencesComputingMilieux_MISCELLANEOUSCancer
researchProduct

Evaluation of halitosis and sialometry in patients submitted to head and neck radiotherapy

2009

Objectives: The aim of this study was to investigate the parameters of halitosis and sialometry in patients who had undergone head and neck radiotherapy, correlating oral concentration of volatile sulfur compounds (VSC) with the presence of tongue coating, salivary flow rate and BANA test. Material and Methods: 35 patients allocated in two groups were examined: group I (control) - patients with systemic and oral health; group II - patients submitted to head and neck radiotherapy. All volunteers were submitted to halitosis measurements through a sulphide monitor, evaluation of tongue coating weight, non-stimulated sialometry and BANA test. Results: The results were analyzed through analysis …

Radiotherapybusiness.industrymedicine.medical_treatmentGroup iiSignificant differenceDentistryHalitosisOral health:CIENCIAS MÉDICAS [UNESCO]XerostomiaRadiation therapyOtorhinolaryngologyHead and neck radiotherapyHead and Neck NeoplasmsBANA testUNESCO::CIENCIAS MÉDICASmedicineHumansSurgeryIn patientbusinessAdverse effectGeneral DentistryMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?

2019

Introduction: Radium-223 (223Ra) improves symptoms and survival in patients with bone metastatic castration-resistant prostate cancer (mCRPC). Study aim: To evaluate the impact of a previous radical prostatectomy (RP) on the outcome of 223Ra therapy in mCRPC patients. The primary prostate tumor left untreated could progress during 223Ra treatment. Materials and methods: mCRPC symptomatic patients treated with 223Ra were enrolled. Luteinizing Hormone-Releasing Hormone analogue was maintained. No other anticancer therapy was given. 223Ra was administered i.v. at the dose of 55 kBq/kg every 4 weeks for 6 cycles. Patients were stratified according to previous RP or not. Hematological toxicity w…

Radium-223Malemedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyUrologyAntineoplastic AgentsBone NeoplasmsSettore MED/24 - UrologiaPrimary tumor03 medical and health sciencesProstate cancer0302 clinical medicineProstateRadium-222medicineHumansAgedProstatectomyRadiotherapybusiness.industryProstatectomyProstateChemoradiotherapy Adjuvantmedicine.diseasePrognosisRadical prostatectomyPrimary tumorSurvival AnalysisRadiation therapyProstatic Neoplasms Castration-Resistantmedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisConcomitantDisease ProgressionCastration resistant prostate cancerNeoplasm GradingRadiopharmaceuticalsbusinessmedicine.drugHormoneFollow-Up StudiesRadiumUrologic oncology
researchProduct

Re-irradiation With Carbon Ion Radiotherapy for Pelvic Rectal Cancer Recurrences in Patients Previously Irradiated to the Pelvis

2020

Background/Aim: Re-irradiation of locally recurrent rectal cancer poses challenges due to the proximity of critical organs, such as the bowel. This study aimed at evaluating the safety and efficacy of re-irradiation with Carbon Ion Radiotherapy (CIRT) in rectal cancer patients with local recurrence. Patients and Methods: Between 2014 and 2018, 14 patients were treated at the National Center of Oncological Hadrontherapy (CNAO Foundation) with CIRT for locally recurrent rectal cancer. Results: All patients concluded the treatment. No G≥3 acute/late reaction nor pelvic infections were observed. The 1-year and 2-year local control rates were, 78% and 52%, respectively, and relapse occurred clos…

Re-IrradiationAdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerHeavy Ion RadiotherapyKaplan-Meier EstimateGeneral Biochemistry Genetics and Molecular BiologyPelvisRe-Irradiation03 medical and health sciences0302 clinical medicineSettore MED/36 - Diagnostica per Immagini e RadioterapiamedicineHumansIn patientRectal cancer recurrenceCarbon ion radiotherapy; Rectal cancer recurrence; Reirradiation; Adult; Aged; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence Local; Pelvis; Prognosis; Rectal Neoplasms; Tomography X-Ray Computed; Treatment Outcome; Heavy Ion Radiotherapy; Re-IrradiationTomographyPelvisRecurrent Rectal CancerReirradiationAgedPharmacologyddc:617business.industryRectal NeoplasmsMiddle Agedmedicine.diseasePrognosisMagnetic Resonance ImagingX-Ray Computedmedicine.anatomical_structureNeoplasm RecurrenceTreatment OutcomeLocalCarbon ion radiotherapy030220 oncology & carcinogenesisMetastasis free survivalCarbon Ion RadiotherapyFemaleRadiologyNeoplasm Recurrence LocalbusinessTomography X-Ray ComputedPelvic InfectionResearch ArticleFollow-Up Studies
researchProduct

Intrauterine device migration into the bladder with stone formation after radiochemotherapy for cervical cancer: a case report

2020

Intrauterine contraceptive device (IUD) is one of the most frequently used contraceptive methods in the world. It is considered a safe and effective method of contraception. However, uterine perfor...

Reoperationmedicine.medical_specialtyMEDLINEUterine Cervical Neoplasms03 medical and health sciences0302 clinical medicinemedicineHumansIntrauterine Device MigrationDevice RemovalCervical cancerUrinary Bladder Calculi030219 obstetrics & reproductive medicineStone formationVesicovaginal FistulaObstetricsbusiness.industryCarcinomaObstetrics and GynecologyChemoradiotherapyCystoscopyMiddle Agedmedicine.diseaseIntrauterine Device Migration030220 oncology & carcinogenesisFemaleLaparoscopyTomography X-Ray ComputedbusinessJournal of Obstetrics and Gynaecology
researchProduct

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer

2016

Background: Trimodality bladder preservation therapy (BPT) in muscle invasive bladder cancer (MIBC) includes a maximal transurethral resection followed by concurrent chemoradiotherapy as an alternative to radical cystectomy (RC) in appropriately selected patients, or as a treatment option in non-cystectomy candidates. Several chemotherapy regimens can be used in BPT, but little is known about current practice patterns. Objective: To describe utilization patterns of BPT and associated survival outcomes in MIBC. Methods: Data were collected from the Retrospective International Study of Cancers of the Urothelial Tract (RISC), a database of 3,024 consecutive patients from 29 international acade…

Research ReportOncologymedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyUrologychemoradiotherapyCystectomy03 medical and health scienceschemistry.chemical_compoundTransitional cell carcinomacystectomy0302 clinical medicineInternal medicinemedicineBladder cancerPerformance statusbusiness.industrymedicine.diseaseCarboplatinGemcitabine3. Good healthRegimenTransitional cell carcinomaOncologychemistrycomparative effectiveness research030220 oncology & carcinogenesisbusinessChemoradiotherapymedicine.drugBladder Cancer
researchProduct

Surface brachytherapy: Joint report of the AAPM and the GEC-ESTRO Task Group No. 253.

2020

The surface brachytherapy Task Group report number 253 discusses the common treatment modalities and applicators typically used to treat lesions on the body surface. Details of commissioning and calibration of the applicators and systems are discussed and examples are given for a risk-based analysis approach to the quality assurance measures that are necessary to consider when establishing a surface brachytherapy program.

Research ReportTask groupmedicine.medical_specialtySurface brachytherapyCalibration (statistics)Computer scienceBrachytherapyRadiotherapy DosageGeneral Medicine030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineTreatment modality030220 oncology & carcinogenesisBody surfaceCalibrationmedicineMedical physicsJoint (geology)Medical physicsREFERENCES
researchProduct

Supplement 2 for the 2004 update of the AAPM Task Group No. 43 Report: Joint recommendations by the AAPM and GEC-ESTRO

2017

Since publication of the 2004 update to the American Association of Physicists in Medicine (AAPM) Task Group No. 43 Report (TG-43U1) and its 2007 supplement (TG-43U1S1), several new low-energy photon-emitting brachytherapy sources have become available. Many of these sources have satisfied the AAPM prerequisites for routine clinical purposes and are posted on the Brachytherapy Seed Registry managed jointly by the AAPM and the Imaging and Radiation Oncology Core Houston Quality Assurance Center (IROC Houston). Given increasingly closer interactions among physicists in North America and Europe, the AAPM and the Groupe Europeen de Curietherapie-European Society for Radiotherapy & Oncology (GEC…

Research Reportmedicine.medical_specialtymedicine.medical_treatmentBrachytherapyBrachytherapy030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineRadiation oncologymedicineHumansDosimetryMedical physicsRadiometryRadiation treatment planningRadiation oncologistPhotonsTask groupbusiness.industryRadiotherapy DosageGeneral MedicineEurope030220 oncology & carcinogenesisPatient dosebusinessMonte Carlo MethodQuality assuranceMedical Physics
researchProduct

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2013

Riskmedicine.medical_specialtyPalliative careColorectal cancermedicine.medical_treatmentColonoscopyAdenocarcinomaRisk AssessmentmedicineHumansNeoplasm MetastasisSigmoidoscopyWnt Signaling PathwayDigital Rectal ExaminationNeoplasm Stagingmedicine.diagnostic_testRectal Neoplasmsbusiness.industryGeneral surgeryCancerSigmoidoscopyChemoradiotherapyHematologymedicine.diseaseColorectal surgerySurgeryEuropeRadiation therapyOncologyNeoplasm Recurrence LocalbusinessColorectal SurgeryChemoradiotherapyFollow-Up StudiesAnnals of Oncology
researchProduct